PATENT CLAIM ANALYSIS

Application Number: 15907672
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["424", "186100"]

Abstract:
The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the  T. gondii  parasite SAGI (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the  T. gondii  parasite.

Claim (Index 9):
A vaccinal composition against Toxoplasmosis, comprising:\n an initial immunization dose adapted for any inoculation route and comprising a recombinant influenza virus of any subtype, and a booster dose adapted for any inoculation route and comprising a MVA virus.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 2.29825
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12808028', '10833744', '10833439', '15512820', '11574285']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.69759256943296
- 35 USC 102 Novelty (BERT): 0.6586764424656901
- Combined Prediction Score: 0.693700956736233
- Mean Citation Score: 426.785624
- Max Citation Score: 733.7252
- Similarity Product: 583.6196482590675

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test